On the 12th, Tobata Lab <4890> announced its financial results for the second quarter of the year ending in March 2025 (April-September 24). The revenue increased by 887.0% compared to the same period last year to 0.486 billion yen, operating profit was 0.069 billion yen (compared to a loss of 0.408 billion yen in the same period last year), ordinary profit was 0.065 billion yen (compared to a loss of 0.403 billion yen), and net profit for the interim was 0.044 billion yen (compared to a loss of 0.293 billion yen).
In research and development, efforts continue to expand collaboration in basic research with joint research institutions to discover new intellectual property and add to the new pipeline. In addition to obtaining results showing the effectiveness of TLG-005 specific clinical research targeting depression and Parkinson's disease, the recruitment of subjects for specific clinical research on eye drops for glaucoma with expanded indications and the development of eye drops to prevent myopia progression (Project TLM-007) have been completed. In research papers, the establishment of the in vitro choroid complex for vascular reactivity screening has been announced.
In business development, rapid progress has been made in entering the high-potential Chinese market. Notably, the company opened an office in the "Eye Valley" in Wenzhou, Zhejiang Province, a central hub of myopia research at the national level in China, becoming the first Japanese company to do so. Additionally, the company's representative, Kazuo Tobata, was appointed as a visiting professor at the Ophthalmology Department of Wenzhou Medical University in Zhejiang. In September, a patent licensing agreement was signed with the major ophthalmic pharmaceutical manufacturer in China, Shenyang Xingqi Pharmaceutical Co., Ltd., in a specific region. This agreement is expected to allow the broad provision of treatment methods based on the company's patents in China.
The performance forecast for the full year of the 2025 fiscal year maintains the initial plan with revenue of 1.2 billion yen, an increase of 78.2% compared to the previous year, operating profit of 0.131 billion yen, ordinary profit of 0.13 billion yen, and net income of 0.1 billion yen.
Comment(0)
Reason For Report